Articles from KCAS Bio

KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms.

KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia. KCAS Bio is a leading international Contract Research Organization (CRO) providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and cell/gene therapy industries. KCAS Bio offers a complete range of bioanalytical services from early discovery support through registration, providing expertise in biological (large molecule), synthetic (small molecule), and cell/gene therapy drug candidates. KCAS Bio provides services from its three locations in Kansas City, KS; the greater Philadelphia, PA, region; and Lyon, France.